Cell and Gene Commercialization

  1. Implementing Complex Ordering Workflows Has Never Been Easier 5/6/2025

    Gain valuable program oversight with real-time monitoring and reporting. Stay informed and in control with comprehensive insights into your cell and gene therapy programs.

  2. Your Ally For Bringing CGTs From Discovery To Delivery 5/6/2025

    Bridging the divide between pioneering Cell and Gene Therapy and patient reality. Learn how focused strategies are empowering Biopharma to deliver life-altering treatments with greater speed and efficiency.

  3. Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D. 5/6/2025

    In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a developer of autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases.

  4. Commercializing Your First CGT: Five Best Practices For Planning 5/6/2025

    From patient identification to reimbursement, commercializing cell and gene therapies is uniquely challenging. Learn five best practices to ensure your innovative CGT reaches the patients who need it.

  5. Enabling Market Access As CGTs Reach More Patients 5/5/2025

    Bringing potentially curative cell and gene therapies to more patients requires a focused approach to market access. Discover essential insights into payer dynamics, pricing innovations, and treatment evolution.

  6. Rethinking CGT Biotech Growth & Investment with Audrey Greenberg 4/8/2025

    On the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track record of launching, scaling, and successfully exiting multi-billion-dollar ventures.

  7. 4 Key Solid Tumor Therapy Objectives iPSCs Can Help Achieve 4/4/2025

    Induced pluripotent stem cells offer some key biologic, technical, and financial advantages over more established PBMC-derived therapies.

  8. Indian Biosimilar Companies Are Poised To Succeed In The Global Market 3/31/2025

    For Indian biosimilar developers looking to capitalize on the upcoming patent cliff, it is vital to play to your strengths and identify strategies for breaking into competitive regulatory markets.

  9. How The Cell And Gene Therapy Market Is Taking Shape 3/31/2025

    Targeting diseases at their genetic root, cell and gene therapies offer unprecedented hope. Yet, the industry grapples with balancing groundbreaking potential against the challenge of high-priced treatments.

  10. 2025 Cell Therapy Outlook From BPI West 3/31/2025

    Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.